APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Diagnostic Radiopharmaceuticals for Alzheimer Disease

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Outlook and Growth Opportunities 2026

Report ID 173984220426 December 2025195 pages

Choose your research edition.

Industry ResearchDiagnostic Radiopharmaceuticals for Alzheimer Disease Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Diagnostic Radiopharmaceuticals for Alzheimer Disease Industry Growth and Trends Forecast to 203271 pages · $3,450 USDMarket StructureGlobal Diagnostic Radiopharmaceuticals for Alzheimer Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Diagnostic Radiopharmaceuticals for Alzheimer Disease market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Diagnostic Radiopharmaceuticals for Alzheimer Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Diagnostic Radiopharmaceuticals for Alzheimer Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Diagnostic Radiopharmaceuticals for Alzheimer Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Diagnostic Radiopharmaceuticals for Alzheimer Disease market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Diagnostic Radiopharmaceuticals for Alzheimer Disease market include Eli Lilly & Co., Life Molecular Imaging Ltd. and GE Healthcare, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Diagnostic Radiopharmaceuticals for Alzheimer Disease market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Diagnostic Radiopharmaceuticals for Alzheimer Disease and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Diagnostic Radiopharmaceuticals for Alzheimer Disease sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Diagnostic Radiopharmaceuticals for Alzheimer Disease market size, projected growth trends, production technologies, key applications, and end-use industries.

Diagnostic Radiopharmaceuticals for Alzheimer Disease Segment by Company

Eli Lilly & Co.

Life Molecular Imaging Ltd.

GE Healthcare, Inc.

Diagnostic Radiopharmaceuticals for Alzheimer Disease Segment by Type

Half Life:1.83 hours

Half Life:1 hours

Diagnostic Radiopharmaceuticals for Alzheimer Disease Segment by Application

Hospital

Clinic

Others

Diagnostic Radiopharmaceuticals for Alzheimer Disease Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Diagnostic Radiopharmaceuticals for Alzheimer Disease status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Diagnostic Radiopharmaceuticals for Alzheimer Disease market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Diagnostic Radiopharmaceuticals for Alzheimer Disease significant trends, drivers, influence factors in global and regions.

6. To analyze Diagnostic Radiopharmaceuticals for Alzheimer Disease competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diagnostic Radiopharmaceuticals for Alzheimer Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diagnostic Radiopharmaceuticals for Alzheimer Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diagnostic Radiopharmaceuticals for Alzheimer Disease.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Diagnostic Radiopharmaceuticals for Alzheimer Disease market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Diagnostic Radiopharmaceuticals for Alzheimer Disease industry.

Chapter 3: Detailed analysis of Diagnostic Radiopharmaceuticals for Alzheimer Disease manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Diagnostic Radiopharmaceuticals for Alzheimer Disease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Diagnostic Radiopharmaceuticals for Alzheimer Disease in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Diagnostic Radiopharmaceuticals for Alzheimer Disease Industry Trends Table 2. Diagnostic Radiopharmaceuticals for Alzheimer Disease Industry Drivers Table 3. Diagnostic Radiopharmaceuticals for Alzheimer Disease Industry Opportunities and Challenges Table 4. Diagnostic Radiopharmaceuticals for Alzheimer Disease Industry Restraints Table 5. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue Share by Company (2021-2026) Table 7. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume Share by Company (2021-2026) Table 9. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Company Ranking, (2024-2026) & (USD Million) Table 11. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Key Company Manufacturing Base & Headquarters Table 12. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Company, Product Type & Application Table 13. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Half Life:1.83 hours Table 18. Significant Companies of Half Life:1 hours Table 19. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume Share by Type (2021-2026) Table 23. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume Share by Type (2027-2032) Table 24. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type (2021-2026) Table 28. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Others Table 32. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume Share by Application (2021-2026) Table 36. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume Share by Application (2027-2032) Table 37. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application (2021-2026) Table 41. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application (2027-2032) Table 42. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region (2021-2026) & (K Units) Table 44. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Region (2021-2026) Table 45. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region (2027-2032) & (K Units) Table 46. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Region (2027-2032) Table 47. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Region (2021-2026) Table 50. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Region (2027-2032) Table 52. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (2021-2026) & (K Units) Table 57. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Country (2021-2026) Table 58. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (2027-2032) & (K Units) Table 59. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Country (2027-2032) Table 60. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Market Share by Country (2021-2026) Table 62. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Market Share by Country (2027-2032) Table 64. Eli Lilly & Co. Company Information Table 65. Eli Lilly & Co. Business Overview Table 66. Eli Lilly & Co. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Eli Lilly & Co. Diagnostic Radiopharmaceuticals for Alzheimer Disease Product Portfolio Table 68. Eli Lilly & Co. Recent Development Table 69. Life Molecular Imaging Ltd. Company Information Table 70. Life Molecular Imaging Ltd. Business Overview Table 71. Life Molecular Imaging Ltd. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Life Molecular Imaging Ltd. Diagnostic Radiopharmaceuticals for Alzheimer Disease Product Portfolio Table 73. Life Molecular Imaging Ltd. Recent Development Table 74. GE Healthcare, Inc. Company Information Table 75. GE Healthcare, Inc. Business Overview Table 76. GE Healthcare, Inc. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. GE Healthcare, Inc. Diagnostic Radiopharmaceuticals for Alzheimer Disease Product Portfolio Table 78. GE Healthcare, Inc. Recent Development Table 79. Key Raw Materials Table 80. Raw Materials Key Suppliers Table 81. Diagnostic Radiopharmaceuticals for Alzheimer Disease Distributors List Table 82. Diagnostic Radiopharmaceuticals for Alzheimer Disease Customers List Table 83. Research Programs/Design for This Report Table 84. Authors List of This Report Table 85. Secondary Sources Table 86. Primary Sources List of Figures Figure 1. Diagnostic Radiopharmaceuticals for Alzheimer Disease Product Image Figure 2. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value (2021-2032) & (US$ Million) Figure 4. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales (2021-2032) & (K Units) Figure 5. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Half Life:1.83 hours Image Figure 10. Half Life:1 hours Image Figure 11. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume Share by Type (2021-2032) Figure 14. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Others Image Figure 20. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume Share by Application (2021-2032) Figure 23. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application (2021-2032) Figure 26. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value (2021-2032) & (US$ Million) Figure 31. North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value (2021-2032) & (US$ Million) Figure 37. South America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Diagnostic Radiopharmaceuticals for Alzheimer Disease Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Half Life:1.83 hours
  • Half Life:1 hours
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Eli Lilly & Co.
  • Life Molecular Imaging Ltd.
  • GE Healthcare, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value (2021-2032)
  4. 1.2.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume (2021-2032)
  5. 1.2.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Dynamics
  1. 2.1 Diagnostic Radiopharmaceuticals for Alzheimer Disease Industry Trends
  2. 2.2 Diagnostic Radiopharmaceuticals for Alzheimer Disease Industry Drivers
  3. 2.3 Diagnostic Radiopharmaceuticals for Alzheimer Disease Industry Opportunities and Challenges
  4. 2.4 Diagnostic Radiopharmaceuticals for Alzheimer Disease Industry Restraints
3 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market by Company
  1. 3.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Company Revenue Ranking in 2025
  2. 3.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Revenue by Company (2021-2026)
  3. 3.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Company (2021-2026)
  4. 3.4 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Average Price by Company (2021-2026)
  5. 3.5 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Company Ranking (2024-2026)
  6. 3.6 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Company Manufacturing Base and Headquarters
  7. 3.7 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Company Product Type and Application
  8. 3.8 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Diagnostic Radiopharmaceuticals for Alzheimer Disease Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market by Type
  1. 4.1 Diagnostic Radiopharmaceuticals for Alzheimer Disease Type Introduction
  2. 4.1.1 Half Life:1.83 hours
  3. 4.1.2 Half Life:1 hours
  4. 4.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Type
  5. 4.2.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Type
  9. 4.3.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Type (2021-2032)
  11. 4.3.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type (2021-2032)
5 Diagnostic Radiopharmaceuticals for Alzheimer Disease Market by Application
  1. 5.1 Diagnostic Radiopharmaceuticals for Alzheimer Disease Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Application
  6. 5.2.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Application
  10. 5.3.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Application (2021-2032)
  12. 5.3.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application (2021-2032)
6 Diagnostic Radiopharmaceuticals for Alzheimer Disease Regional Sales and Value Analysis
  1. 6.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region (2021-2032)
  3. 6.2.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region: 2021-2026
  4. 6.2.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Region (2027-2032)
  5. 6.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Region (2021-2032)
  7. 6.4.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Region: 2021-2026
  8. 6.4.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Region (2027-2032)
  9. 6.5 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value (2021-2032)
  12. 6.6.2 North America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value (2021-2032)
  15. 6.7.2 Europe Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value (2021-2032)
  21. 6.9.2 South America Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Country, 2025 VS 2032
7 Diagnostic Radiopharmaceuticals for Alzheimer Disease Country-level Sales and Value Analysis
  1. 7.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (2021-2032)
  4. 7.3.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (2021-2026)
  5. 7.3.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales by Country (2027-2032)
  6. 7.4 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Country (2021-2032)
  7. 7.4.1 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Country (2021-2026)
  8. 7.4.2 Global Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly & Co.
  2. 8.1.1 Eli Lilly & Co. Company Information
  3. 8.1.2 Eli Lilly & Co. Business Overview
  4. 8.1.3 Eli Lilly & Co. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly & Co. Diagnostic Radiopharmaceuticals for Alzheimer Disease Product Portfolio
  6. 8.1.5 Eli Lilly & Co. Recent Developments
  7. 8.2 Life Molecular Imaging Ltd.
  8. 8.2.1 Life Molecular Imaging Ltd. Company Information
  9. 8.2.2 Life Molecular Imaging Ltd. Business Overview
  10. 8.2.3 Life Molecular Imaging Ltd. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Life Molecular Imaging Ltd. Diagnostic Radiopharmaceuticals for Alzheimer Disease Product Portfolio
  12. 8.2.5 Life Molecular Imaging Ltd. Recent Developments
  13. 8.3 GE Healthcare, Inc.
  14. 8.3.1 GE Healthcare, Inc. Company Information
  15. 8.3.2 GE Healthcare, Inc. Business Overview
  16. 8.3.3 GE Healthcare, Inc. Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GE Healthcare, Inc. Diagnostic Radiopharmaceuticals for Alzheimer Disease Product Portfolio
  18. 8.3.5 GE Healthcare, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Diagnostic Radiopharmaceuticals for Alzheimer Disease Value Chain Analysis
  2. 9.1.1 Diagnostic Radiopharmaceuticals for Alzheimer Disease Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Mode & Process
  6. 9.2 Diagnostic Radiopharmaceuticals for Alzheimer Disease Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Diagnostic Radiopharmaceuticals for Alzheimer Disease Distributors
  9. 9.2.3 Diagnostic Radiopharmaceuticals for Alzheimer Disease Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst